So...trimesta is estriol. Can only be used on women.BioIdentical hormone long prescribed for compounding. Very little hope of any protective ip wrap if not combined with a drug. Copaxone great choice for combo study because copaxones lack of year one efficacy well known, so combo trial would allow estriol efficacy to be clearly measured. Voskhul has been working with estriol forever, thru UCLA with grants and support from ms foundation. Having SYN in its old incarnation offer support for drug trial allowed her to continue development. MS foundation footed bill. SYN able to secure ip on combos. Win-win for SYN.
Market Data 
Markets 
AI
